Abstract
Photodynamic therapy (PDT) can lead to the creation of heterogeneous, response-limiting hypoxia during illumination, which may be controlled in part through illumination fluence rate. In the present report we consider (1) regional differences in hypoxia, vascular response, and cell kill as a function of tumor depth and (2) the role of fluence rate as a mediator of depth-dependent regional intratumor heterogeneity. Intradermal RIF murine tumors were treated with Photofrin PDT using surface illumination at an irradiance of 75 or 38 mW cm-2. Regional heterogeneity in tumor response was examined through comparison of effects in the surfacevs. base of tumors, i.e. along a plane parallel to the skin surface and perpendicular to the incident illumination. 75 mW cm-2 PDT created significantly greater hypoxia in tumor bases relative to their surfaces. Increased hypoxia in the tumor base could not be attributed to regional differences in Photofrin concentration nor effects of fluence rate distribution on photochemical oxygen consumption, but significant depth-dependent heterogeneity in vascular responses and cytotoxic response were detected. At a lower fluence rate of 38 mW cm-2, no detectable regional differences in hypoxia or cytotoxic responses were apparent, and heterogeneity in vascular response was significantly less than that during 75 mW cm-2 PDT. This research suggests that the benefits of low-fluence-rate PDT are mediated in part by a reduction in intratumor heterogeneity in hypoxic, vascular and cytotoxic responses.
Similar content being viewed by others
Abbreviations
- DCS:
-
Diffuse correlation spectroscopy
- EF3:
-
[(2-(2-Nitroimidazol-1H-yl)-N-(3,3,3-trifluoropropyl) acetamide)
- HPPH:
-
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a
- PDT:
-
Photodynamic therapy
- THC:
-
Total hemoglobin concentration
References
S. Coutier, L. N. Bezdetnaya, T. H. Foster, R. M. Parache, F. Guillemin, Effect of irradiation fluence rate on the efficacy of photodynamic therapy and tumor oxygenation in meta-tetra (hydroxyphenyl) chlorin (mTHPC)-sensitized HT29 xenografts in nude mice, Radiat. Res., 2002, 158, 339–345.
T. M. Sitnik, B. W. Henderson, The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy, Photochem. Photobiol., 1998, 67, 462–466.
E. Angell-Petersen, S. Spetalen, S. J. Madsen, C. H. Sun, Q. Peng, S. W. Carper, M. Sioud, H. Hirschberg, Influence of light fluence rate on the effects of photodynamic therapy in an orthotopic rat glioma model, J. Neurosurg., 2006, 104, 109–117.
T. M. Busch, E. P. Wileyto, M. J. Emanuele, F. Del Piero, L. Marconato, E. Glatstein, C. J. Koch, Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen, Cancer Res., 2002, 62, 7273–7279.
B. W. Henderson, T. M. Busch, J. W. Snyder, Fluence rate as a modulator of PDT mechanisms, Lasers Surg. Med., 2006, 38, 489–493.
S. Iinuma, K. T. Schomacker, G. Wagnieres, M. Rajadhyaksha, M. Bamberg, T. Momma, T. Hasan, In vivo fluence rate and fractionation effects on tumor response and photobleaching: photodynamic therapy with two photosensitizers in an orthotopic rat tumor model, Cancer Res., 1999, 59, 6164–6170.
M. B. Ericson, C. Sandberg, B. Stenquist, F. Gudmundson, M. Karlsson, A. M. Ros, A. Rosen, O. Larko, A. M. Wennberg, I. Rosdahl, Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome, Br. J. Dermatol., 2004, 151, 1204–1212.
B. W. Henderson, S. O. Gollnick, J. W. Snyder, T. M. Busch, P. C. Kousis, R. T. Cheney, J. Morgan, Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors, Cancer Res., 2004, 64, 2120–2126.
K. K. Wang, S. Mitra, T. H. Foster, A comprehensive mathematical model of microscopic dose deposition in photodynamic therapy, Med. Phys., 2007, 34, 282–293.
H. W. Wang, T. C. Zhu, M. E. Putt, M. Solonenko, J. Metz, A. Dimofte, J. Miles, D. L. Fraker, E. Glatstein, S. M. Hahn, A. G. Yodh, Broadband reflectance measurements of light penetration, blood oxygenation, hemoglobin concentration, and drug concentration in human intraperitoneal tissues before and after photodynamic therapy, J. Biomed. Opt., 2005, 10, 14004.
C. Holmer, K. S. Lehmann, J. Wanken, C. Reissfelder, A. Roggan, G. Mueller, H. J. Buhr, J. P. Ritz, Optical properties of adenocarcinoma and squamous cell carcinoma of the gastroesophageal junction, J. Biomed. Opt., 2007, 12, 014025.
S. Mitra, T. H. Foster, Carbogen breathing significantly enhances the penetration of red light in murine tumours in vivo, Phys. Med. Biol., 2004, 49, 1891–1904.
T. M. Busch, E. P. Wileyto, S. M. Evans, C. J. Koch, Quantitative spatial analysis of hypoxia and vascular perfusion in tumor sections, Adv. Exp. Med. Biol., 2003, 510, 37–43.
H.-W. Wang, E. Rickter, M. Yuan, E. P. Wileyto, E. Glatstein, A. Yodh, T. M. Busch, Effect of photosensitizer dose on fluence rate responses to photodynamic therapy, Photochem. Photobiol., 2007, 83, 1040–1048.
H. W. Wang, M. E. Putt, M. J. Emanuele, D. B. Shin, E. Glatstein, A. G. Yodh, T. M. Busch, Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome, Cancer Res., 2004, 64, 7553–7561.
G. Yu, T. Durduran, C. Zhou, H. W. Wang, M. E. Putt, H. M. Saunders, C. M. Sehgal, E. Glatstein, A. G. Yodh, T. M. Busch, Noninvasive monitoring of murine tumor blood flow during and after photodynamic therapy provides early assessment of therapeutic efficacy, Clin. Cancer Res., 2005, 11, 3543–3552.
T. M. Busch, S. M. Hahn, E. P. Wileyto, C. J. Koch, D. L. Fraker, P. Zhang, M. Putt, K. Gleason, D. B. Shin, M. J. Emanuele, K. Jenkins, E. Glatstein, S. M. Evans, Hypoxia and Photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients, Clin. Cancer Res., 2004, 10, 4630–4638.
T. M. Sitnik, J. A. Hampton, B. W. Henderson, Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate, Br. J. Cancer, 1998, 77, 1386–1394.
M. Seshadri, J. A. Spernyak, R. Mazurchuk, S. H. Camacho, A. R. Oseroff, R. T. Cheney, D. A. Bellnier, Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy, Clin. Cancer Res., 2005, 11, 4241–4250.
K. P. Nielsen, A. Juzeniene, P. Juzenas, K. Stamnes, J. J. Stamnes, J. Moan, Choice of optimal wavelength for PDT: the significance of oxygen depletion, Photochem. Photobiol., 2005, 81, 1190–1194.
A. R. Pries, A. J. Cornelissen, A. A. Sloot, M. Hinkeldey, M. R. Dreher, M. Hopfner, M. W. Dewhirst, T. W. Secomb, Structural adaptation and heterogeneity of normal and tumor microvascular networks, PLoS Comput. Biol., 2009, 5, e1000394.
B. Chen, B. W. Pogue, P. J. Hoopes, T. Hasan, Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy, Int. J. Radiat. Oncol., Biol., Phys., 2005, 61, 1216–1226.
B. Dome, S. Paku, B. Somlai, J. Timar, Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance, J. Pathol., 2002, 197, 355–362.
Y. Pina, C. M. Cebulla, T. G. Murray, A. Alegret, S. R. Dubovy, H. Boutrid, W. Feuer, L. Mutapcic, M. E. Jockovich, Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculature, Ophthalmic Res., 2009, 41, 160–169.
S. Kupesic, A. Kurjak, Contrast-enhanced, three-dimensional power Doppler sonography for differentiation of adnexal masses, Obstet. Gynecol., 2000, 96, 452–458.
J. A. Nagy, S. H. Chang, A. M. Dvorak, H. F. Dvorak, Why are tumour blood vessels abnormal and why is it important to know?, Br. J. Cancer, 2009, 100, 865–869.
D. Fukumura, R. K. Jain, Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization, Microvasc. Res., 2007, 74, 72–84.
J. H. Woodhams, A. J. Macrobert, S. G. Bown, The role of oxygen monitoring during photodynamic therapy and its potential for treatment dosimetry, Photochem. Photobiol. Sci., 2007, 6, 1246–1256.
T. M. Busch, Local physiological changes during photodynamic therapy, Lasers Surg. Med., 2006, 38, 494–499.
W. J. Cottrell, A. D. Paquette, K. R. Keymel, T. H. Foster, A. R. Oseroff, Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas, Clin. Cancer Res., 2008, 14, 4475–4483.
T. H. Foster, R. S. Murant, R. G. Bryant, R. S. Knox, S. L. Gibson, R. Hilf, Oxygen consumption and diffusion effects in photodynamic therapy, Radiat. Res., 1991, 126, 296–303.
M. Seshadri, D. A. Bellnier, L. A. Vaughan, J. A. Spernyak, R. Mazurchuk, T. H. Foster, B. W. Henderson, Light delivery over extended time periods enhances the effectiveness of photodynamic therapy, Clin. Cancer Res., 2008, 14, 2796–2805.
T. M. Busch, S. M. Hahn, S. M. Evans, C. J. Koch, Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3,-trifluoropropyl)acetamide], Cancer Res., 2000, 60, 2636–2642.
Author information
Authors and Affiliations
Corresponding author
Additional information
† Electronic supplementary information (ESI) available: Fig. S1 (fluence rate as a function of tumor depth); Fig. S2 (EF3 binding level). See DOI: 10.1039/b9pp00004f
‡ These authors contributed equally to this work
Rights and permissions
About this article
Cite this article
Busch, T.M., Xing, X., Yu, G. et al. Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy. Photochem Photobiol Sci 8, 1683–1693 (2009). https://doi.org/10.1039/b9pp00004f
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1039/b9pp00004f